Canagliflozin/metformin

Canagliflozin/metformin, sold under the brand name Vokanamet among others, is a fixed-dose combination anti-diabetic medication used for the treatment of type 2 diabetes. It is used in combination with diet and exercise. It is taken by mouth.
The most common side effects include hypoglycemia when used in combination with insulin or a sulphonylurea and vulvovaginal candidiasis.
Canagliflozin/metformin was approved for medical use in the European Union in April 2014, and for use in the United States in August 2014.

Medical uses

Canagliflozin/metformin is indicated in adults aged 18 years of age and older with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control.

Adverse effects

To lessen the risk of developing ketoacidosis after surgery, the FDA approved changes to the prescribing information for SGLT2 inhibitor diabetes medicines to recommend they be stopped temporarily before scheduled surgery. Canagliflozin, dapagliflozin, and empagliflozin should each be stopped at least three days before, and ertugliflozin should be stopped at least four days before scheduled surgery.
Symptoms of ketoacidosis include nausea, vomiting, abdominal pain, tiredness, and trouble breathing.